Last edition
News about Clinical Trials
Akeso Initiates Phase 2 Trial of TROP2/Nectin-4 Bispecific ADC in Advanced Breast Cancer
Akeso has dosed the first patient in a Phase 2 study of AK146D1 combined with ivonescimab, advancing its next-generation “IO2.0 + ADC2.0” approach for advanced breast cancer.
Clinical Trials | 10/08/2026 | By News Bureau
World-First Fridge-Free Tetanus-Diphtheria Vaccine Trial Shows Promising Results
Stablepharma’s SPVX02 remains potent for up to two years at temperatures of up to 30°C, potentially reducing cold-chain dependence, vaccine wastage and barriers to immunisation in remote regions.
Clinical Trials | 10/08/2026 | By News Bureau
Obsidian Enrols First Patient in Pivotal-Pathway Study of Engineered TIL Therapy
The phase 1/2 Agni-01 cohort will evaluate amsoki-cel in ICI-resistant advanced melanoma, with enrollment expected to conclude by Q1 2027 and topline data anticipated by year-end 2027.<br />
Clinical Trials | 10/08/2026 | By News Bureau
Damora Therapeutics Launches Global Phase 1/1b Trial of DMR-001 for mutCALR-Driven Blood Cancers
Damora Therapeutics initiates the global CLARITY-101 clinical trial to assess DMR-001, a novel mutation-targeted therapy designed to address the underlying cause of mutCALR-driven blood disorders.
Clinical Trials | 07/08/2026 | By News Bureau
Marvel Biosciences Reports Positive Preclinical Results for MB-204 in Fragile X Syndrome Study
Marvel Biosciences has reported positive preclinical results for its lead drug candidate, MB-204, in a Fragile X syndrome study conducted with the FRAXA Research Foundation. The findings further support the therapy's potential to treat autism spectrum disorder and related neurodevelopmental conditions.
Clinical Trials | 06/08/2026 | By News Bureau
Innovent Doses First Patient in Pivotal IBI363/TAK-928 CRC Study
Innovent has dosed the first patient in its pivotal IBI363/TAK-928 study, advancing next-generation immunotherapy for colorectal cancer.
Clinical Trials | 06/08/2026 | By News Bureau | 272
4Moving Biotech has completed patient enrollment in its global Phase 2a INFLAM MOTION trial, assessing the safety and efficacy of investigational therapy 4P004 for inflammatory knee osteoarthritis.
Clinical Trials | 05/08/2026 | By News Bureau | 363
Otsuka's Voyxact Meets Key Phase 3 Endpoint in IgA Nephropathy Study
Otsuka presented new Phase 3 VISIONARY trial findings showing that Voyxact significantly slowed kidney function decline over two years, reinforcing its potential as a disease-modifying therapy for adults with primary IgA nephropathy.
Clinical Trials | 05/08/2026 | By News Bureau
AusperBio Doses First Patient in HBV Candidate AHB-171 Study
AusperBio has dosed the first patient in the AHB-171 clinical study, advancing its HBV pipeline and proprietary Au-HALO liver-targeting delivery technology siRNA platform.
Clinical Trials | 03/08/2026 | By News Bureau
Novo Nordisk Provides Phase 3 ZEUS Trial Update
Novo Nordisk shared an update on the phase 3 ZEUS trial evaluating patients with ASCVD, CKD and inflammation enrolled in a placebo-controlled study.
Clinical Trials | 03/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy